[Genetic polymorphism and drug interactions: their importance in the treatment of pain].

[1]  G. Olsson.  The genetics of pain: Progress in pain research and management , 2007 .

[2]  Y. Daali,et al.  Codeine intoxication associated with ultrarapid CYP2D6 metabolism. , 2004, The New England journal of medicine.

[3]  E. Sellers,et al.  Pharmacokinetics of Dextromethorphan After Single or Multiple Dosing in Combination With Quinidine in Extensive and Poor Metabolizers , 2004, Journal of clinical pharmacology.

[4]  Y. Daali,et al.  A simplified analytical method for a phenotyping cocktail of major CYP450 biotransformation routes. , 2004, Journal of pharmaceutical and biomedical analysis.

[5]  E. Kharasch,et al.  The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. , 2004, British journal of clinical pharmacology.

[6]  C. McCartney,et al.  A Qualitative Systematic Review of the Role of N-Methyl-d-Aspartate Receptor Antagonists in Preventive Analgesia , 2004, Anesthesia and analgesia.

[7]  D. Grothe,et al.  Treatment of Pain Syndromes with Venlafaxine , 2004, Pharmacotherapy.

[8]  Magnus Ingelman-Sundberg,et al.  Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. , 2004, Trends in pharmacological sciences.

[9]  E. Kharasch,et al.  Quinidine as a Probe for the Role of P‐Glycoprotein in the Intestinal Absorption and Clinical Effects of Fentanyl , 2004, Journal of clinical pharmacology.

[10]  Honghui Zhou,et al.  “Cocktail” Approaches and Strategies in Drug Development: Valuable Tool or Flawed Science? , 2004, Journal of clinical pharmacology.

[11]  Thierry Buclin,et al.  Polymorphisms in Human MDR1 (P‐glycoprotein): Recent Advances and Clinical Relevance , 2004, Clinical pharmacology and therapeutics.

[12]  E. Kharasch,et al.  Role of P‐glycoprotein in the intestinal absorption and clinical effects of morphine , 2003, Clinical pharmacology and therapeutics.

[13]  C. Handschin,et al.  Induction of Drug Metabolism: The Role of Nuclear Receptors , 2003, Pharmacological Reviews.

[14]  J. Lötsch,et al.  Effects of ABCB1 (multidrug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers. , 2003, Pharmacogenetics.

[15]  I. Cascorbi.  Pharmacogenetics of cytochrome P4502D6: genetic background and clinical implication , 2003, European journal of clinical investigation.

[16]  J. Lötsch,et al.  Respiratory and miotic effects of morphine in healthy volunteers when P‐glycoprotein is blocked by quinidine , 2003, Clinical pharmacology and therapeutics.

[17]  A. Hoeft,et al.  Impact of CYP2D6 genotype on postoperative tramadol analgesia , 2003, Pain.

[18]  C. Meisel,et al.  Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites. , 2003, Pharmacogenetics.

[19]  Ilkka Ojanperä,et al.  Post-mortem SNP analysis of CYP2D6 gene reveals correlation between genotype and opioid drug (tramadol) metabolite ratios in blood. , 2003, Forensic science international.

[20]  A. Morice,et al.  Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan vs. dextrorphan using quinidine inhibition. , 2003, British journal of clinical pharmacology.

[21]  C. Eap,et al.  Cytochrome P4503A4 metabolic activity, methadone blood concentrations, and methadone doses. , 2003, Drug and alcohol dependence.

[22]  A. Nafziger,et al.  Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. , 2002, The American journal of medicine.

[23]  U. Brinkmann,et al.  Modulation of steady‐state kinetics of digoxin by haplotypes of the P‐glycoprotein MDR1 gene , 2002, Clinical pharmacology and therapeutics.

[24]  U. Yasar,et al.  Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase. , 2002, British journal of clinical pharmacology.

[25]  C. Meisel,et al.  Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2 , 2002, Clinical pharmacology and therapeutics.

[26]  R. Tyndale,et al.  Treatment of Codeine Dependence With Inhibitors of Cytochrome P450 2D6 , 2002, Journal of clinical psychopharmacology.

[27]  R. Kim,et al.  Interaction of Morphine, Fentanyl, Sufentanil, Alfentanil, and Loperamide with the Efflux Drug Transporter P-glycoprotein , 2002, Anesthesiology.

[28]  C. Eap,et al.  Paroxetine Increases Steady-State Concentrations of (R)-Methadone in CYP2D6 Extensive but Not Poor Metabolizers , 2002, Journal of clinical psychopharmacology.

[29]  L. Bertilsson,et al.  Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. , 2002, British journal of clinical pharmacology.

[30]  J. Zadina,et al.  MDR1 P-glycoprotein transports endogenous opioid peptides , 2001, Peptides.

[31]  Erik Eliasson,et al.  The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro , 2001, European Journal of Clinical Pharmacology.

[32]  M. Ingelman-Sundberg,et al.  Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. , 2001, British journal of clinical pharmacology.

[33]  S. Kasper,et al.  CYP2D6 and CYP2C19 genotype‐based dose recommendations for antidepressants:
a first step towards subpopulation‐specific dosages , 2001, Acta psychiatrica Scandinavica.

[34]  S. Higuchi,et al.  Genetic polymorphisms and functional characterization of the 5′‐flanking region of the human CYP2C9 gene: In vitro and in vivo studies , 2001, Clinical pharmacology and therapeutics.

[35]  M. Kennedy,et al.  Is cytochrome P450 2C9 genotype associated with NSAID gastric ulceration? , 2001, British journal of clinical pharmacology.

[36]  Ann Daly,et al.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression , 2001, Nature Genetics.

[37]  M. Preisig,et al.  Cytochrome P450 2D6 Genotype and Methadone Steady-State Concentrations , 2001, Journal of clinical psychopharmacology.

[38]  H. McLeod,et al.  MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. , 2001, Pharmacogenetics.

[39]  W. Haefeli,et al.  Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine. , 2000, British journal of clinical pharmacology.

[40]  C. Wandel,et al.  Increased drug delivery to the brain by P‐glycoprotein inhibition , 2000, Clinical pharmacology and therapeutics.

[41]  G. Aithal,et al.  Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. , 2000, Pharmacogenetics.

[42]  C. Bernards,et al.  Opiate-induced Analgesia Is Increased and Prolonged in Mice Lacking P-glycoprotein , 2000, Anesthesiology.

[43]  A. Nafziger,et al.  Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. , 2000, Pharmacogenetics.

[44]  U. Brinkmann,et al.  Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Kaoru Kobayashi,et al.  CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. , 2000, Pharmacogenetics.

[46]  P. Marchettini,et al.  COMMENTARY: THE PERIPHERAL MECHANISMS OF ABNORMAL TEMPORAL SUMMATION , 2000, European journal of pain.

[47]  D. Fishbain.  Evidence-based data on pain relief with antidepressants , 2000, Annals of medicine.

[48]  M. Relling,et al.  Pharmacogenomics: translating functional genomics into rational therapeutics. , 1999, Science.

[49]  M. Ingelman-Sundberg,et al.  Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. , 1999, Trends in pharmacological sciences.

[50]  J. Sheller,et al.  Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects. , 1999, The Journal of pharmacology and experimental therapeutics.

[51]  P. Dayer,et al.  Contribution of cytochrome P-4502D6 phenotype to the neuromodulatory effects of dextromethorphan. , 1999, The Journal of pharmacology and experimental therapeutics.

[52]  E. Kalso,et al.  Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone , 1998, Clinical pharmacology and therapeutics.

[53]  R. Tyndale,et al.  Relevance of deficient CYP2D6 in opiate dependence , 1998 .

[54]  G. M. Pollack,et al.  Altered disposition and antinociception of [D-penicillamine(2,5)] enkephalin in mdr1a-gene-deficient mice. , 1998, The Journal of pharmacology and experimental therapeutics.

[55]  M. Eichelbaum,et al.  Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation , 1998, Pain.

[56]  K. Brouwer,et al.  Effect of GF120918, a Potent P-glycoprotein Inhibitor, on Morphine Pharmacokinetics and Pharmacodynamics in the Rat , 1998, Pharmaceutical Research.

[57]  L. Bertilsson,et al.  10‐hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes , 1998, Clinical pharmacology and therapeutics.

[58]  F. Berthou,et al.  Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[59]  R. Tyndale,et al.  Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence. , 1997, Pharmacogenetics.

[60]  E. Kharasch,et al.  Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[61]  E. Kharasch,et al.  The Role of Cytochrome P450 3A4 in Alfentanil Clearance: Implications for Interindividual Variability in Disposition and Perioperative Drug Interactions , 1997, Anesthesiology.

[62]  G. Granneman,et al.  Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions , 1997, Clinical pharmacokinetics.

[63]  H. Kroemer,et al.  Use of Probe Drugs as Predictors of Drug Metabolism in Humans , 1997, Journal of clinical pharmacology.

[64]  L. Arendt-Nielsen,et al.  The hypoalgesic effect of tramadol in relation to CYP2D6 * , 1996, Clinical pharmacology and therapeutics.

[65]  R. Blouin,et al.  The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: Screening costs and influence on clinical outcomes in psychiatry , 1996, Clinical pharmacology and therapeutics.

[66]  L. Bertilsson,et al.  Geographical/Interracial Differences in Polymorphic Drug Oxidation , 1995, Clinical pharmacokinetics.

[67]  E. Sellers,et al.  CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone , 1993, Clinical pharmacology and therapeutics.

[68]  J. Svensson,et al.  Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine. , 1991, British journal of clinical pharmacology.

[69]  S. Preskorn,et al.  Central Nervous System Toxicity of Tricyclic Antidepressants: Phenomenology, Course, Risk Factors, and Role of Therapeutic Drug Monitoring , 1990, Journal of clinical psychopharmacology.

[70]  P. Dayer,et al.  [Drug interactions of midazolam]. , 1989, Schweizerische medizinische Wochenschrift.

[71]  P. Dayer,et al.  Dextromethorphan O‐demethylation in liver microsomes as a prototype reaction to monitor cytochrome P‐450 db1 activity , 1989, Clinical pharmacology and therapeutics.

[72]  T. Leemann,et al.  Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI). , 1988, Biochemical and biophysical research communications.

[73]  O. Mcbride,et al.  Human P450PCN1: sequence, chromosome localization, and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase. , 1988, DNA.

[74]  I. Pastan,et al.  Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[75]  P. Dayer,et al.  Impact of environmental and genetic factors on codeine analgesia , 2004, European Journal of Clinical Pharmacology.

[76]  L. Arendt-Nielsen,et al.  The effect of quinidine on the analgesic effect of codeine , 2004, European Journal of Clinical Pharmacology.

[77]  P. Jannetto,et al.  Pharmacogenomic genotyping methodologies , 2004, Clinical chemistry and laboratory medicine.

[78]  P. Dayer,et al.  In vitro forecasting of drugs which may interfere with the biotransformation of midazolam , 2004, European Journal of Clinical Pharmacology.

[79]  P. Dayer,et al.  La glycoprotéine P : un transporteur de médicaments à ne pas négliger , 2004, Revue Médicale Suisse.

[80]  J. Desmeules,et al.  La glycoprotéine P : un transporteur de médicaments à ne pas négliger : Thérapeutique , 2004 .

[81]  C. Meisel,et al.  Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. , 2003, British journal of clinical pharmacology.

[82]  U. Hofmann,et al.  Influence of Age and Cytochrome P450 2C9 Genotype on the Steady-State Disposition of Diclofenac and Celecoxib , 2003, Clinical pharmacokinetics.

[83]  Mikko Niemi,et al.  Pharmacokinetic Interactions with Rifampicin , 2003, Clinical pharmacokinetics.

[84]  Ulrich M. Zanger,et al.  Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry , 2003, Naunyn-Schmiedeberg's Archives of Pharmacology.

[85]  T. Buclin,et al.  Interindividual Variability of the Clinical Pharmacokinetics of Methadone , 2002, Clinical pharmacokinetics.

[86]  T. Kubota,et al.  Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9*3 allele , 2000, European Journal of Clinical Pharmacology.

[87]  J. Spence,et al.  Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 Inhibition , 2000, Clinical pharmacokinetics.

[88]  J. Desmeules.  The tramadol option. , 2000, European journal of pain.

[89]  F. Collins.  Microarrays and macroconsequences , 1999, Nature Genetics.

[90]  H. Dengler,et al.  PHARMACOKINETICS AND DISPOSITION , 1997 .

[91]  L. Arendt-Nielsen,et al.  Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects , 1996, European Journal of Clinical Pharmacology.

[92]  F. Gonzalez,et al.  Molecular genetics of the P-450 superfamily. , 1990, Pharmacology & therapeutics.